Machine-learning-driven drug discovery and development company Insitro announced today that it raised $143 million in an oversubscribed Series B financing round.
San Francisco-based Insitro said in a news release that it plans to use the funds to build its foundations of technology and automation, enabling data generation at a larger scale, expanding its capabilities for creating predictive models of human disease.
Get the full story at our sister site, Drug Discovery & Development.
Machine-learning-driven drug discovery and development company Insitro announced today that it raised $143 million in an oversubscribed Series B financing round.
San Francisco-based Insitro said in a news release that it plans to use the funds to build its foundations of technology and automation, enabling data generation at a larger scale, expanding its capabilities for creating predictive models of human disease.
The company also plans to use the money for helping to identify patient segmentation biomarkers and advancing therapeutics in genetically-defined patient populations. Other uses of the funds include building partnerships along the R&D chain to accelerate drug discovery and development.
Insitro is working on applying bioengineering technologies to creating data sets that allow for machine learning methods to assist in pharmaceutical R&D.
“Since our founding, insitro has been focused on building a data-driven drug discovery and de…